ALSO READWockhardt gets shareholders' nod for raising Rs 1,000 cr via QIP route Wockhardt's Ankaleshwar facility gets clearance from German regulator Wockhardt settles with Teva and its affiliate in London High Court RIL shares worth Rs 50,000-cr change hands on BSE Airtel shares see sharp recovery, surge 8%
Drug firm Wockhardt has received approval from the US health regulator for generic Olopatadine HCl eye drops used for the treatment of opthalmic allergies. The company has received final approval from the United States Food and Drug Administration (USFDA) for Olopatadine HCl 0.1 per cent opthalmic solution, Wockhardt said in a BSE filing today. The product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis, it added. The product will be manufactured at a USFDA approved contract manufacturing organisation based in Montreal, Canada, Wockhardt said. Shares of Wockhardt today closed 0.18 per cent higher at Rs 605.05 per scrip on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)